Neuraminidase inhibitors for influenza

New England Journal of Medicine

Volumn 353, Issue 13, 2005, Pages 1363-1373

  Moscona, Anne ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE; AMANTADINE; ANTIVIRUS AGENT; INFLUENZA VACCINE; OSELTAMIVIR; RIMANTADINE; SIALIDASE INHIBITOR; ZANAMIVIR;

ABDOMINAL PAIN; ALLERGY; AVIAN INFLUENZA; BRONCHITIS; BRONCHOSPASM; CHRONOTHERAPY; CLINICAL TRIAL; CONFUSION; COUGHING; DIABETES MELLITUS; DIARRHEA; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DYSPNEA; EAR INFECTION; EAR NOSE THROAT DISEASE; FACE EDEMA; FATIGUE; FEVER; HEADACHE; HEART ARRHYTHMIA; HEPATITIS; HUMAN; INFLUENZA; INFLUENZA VIRUS A; INSOMNIA; LUNG DISEASE; META ANALYSIS; NAUSEA; NONHUMAN; NOSE DISEASE; NOSE INFECTION; OTITIS MEDIA; PHARYNGITIS; PRIORITY JOURNAL; PROPHYLAXIS; PSEUDOMEMBRANOUS COLITIS; RASH; REVIEW; SEIZURE; SINUSITIS; SYNCOPE; SYSTEMATIC REVIEW; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; URTICARIA; VERTIGO; VIRUS TRANSMISSION; VOMITING;

ACETAMIDES; ADAMANTANE; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; DISEASE OUTBREAKS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; GUANIDINES; HUMANS; INFLUENZA A VIRUS; INFLUENZA, HUMAN; NEURAMINIDASE; OSELTAMIVIR; PYRANS; SIALIC ACIDS; ZANAMIVIR;

EID: 25444501243     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra050740     Document Type: Review

References (67)

1. Hayden FG. Pandemic influenza: is an antiviral response realistic? Pediatr Infect Dis J 2004;23:Suppl:S262-S269.
2. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 2004;78:12665-7.
3. Meindl P, Bodo G, Palese P, Schulman J, Tuppy H. Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virology 1974;58:457-63.
4. Palese P, Compans RW. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J Gen Virol 1976;33:159-63.
5. Palese P, Schulman JL, Bodo G, Meindl P. Inhibition of influenza and parainfluenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N- trifluoroacetylneuraminic acid (FANA). Virology 1974;59:490-8.
6. Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983;303:41-4.
7. Varghese JN, McKimm-Breschkin JL, Caldwell JB, Kortt AA, Colman PM. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 1992;14:327-32.
8. von Itzstein M, Wu W-Y, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993;363:418-23.
9. Varghese JN, Epa VC, Colman PM. Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase. Protein Sci 1995;4:1081-7.
10. Kim CU, Lew W, Williams MA, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 1997;119:681-90.
11. Cass LM, Brown J, Pickford M, et al. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet 1999;36:Suppl 1:21-31.
12. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med 1997;337:874-80.
13. Cooper NJ, Sutton AJ, Abrams KR, Wailoo A, Turner D, Nicholson KG. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003;326:1235.
14. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999;180:254-61.
15. Makela MJ, Pauksens K, Rostila T, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect 2000;40:42-8.
16. The MIST (Management of Influenza in the Southern Hemisphere Trialist) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998;352:1877-81. [Errata, Lancet 1999;353:504, 1104.]
17. Matsumoto K, Ogawa N, Nerome K, et al. Safety and efficacy of the neuraminidase inhibitor zanamivir in treating influenza virus infection in adults: results from Japan. Antivir Ther 1999;4:61-8.
18. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. JAMA 2000;283:1016-24.
19. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Lancet 2000;355:1845-50. [Erratum, Lancet 2000;356:1856.]
20. Murphy KR, Eivindson A, Pauksens K, et al. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease: a double-blind, randomised, placebo-controlled, multicentre study. Clin Drug Investig 2000;20:337-49.
21. Hedrick JA, Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J 2000;19:410-7.
22. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001;20: 127-33. [Erratum, Pediatr Infect Dis J 2001;20:421.]
23. Aoki FY, Macleod MD, Paggiaro P, et al. Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003;51:123-9.
24. Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003;163:1667-72.
25. Kawai N, Ikematsu H, Iwaki N, et al. Factors influencing the effectiveness of oseltamivir and amantadine for the treatment of influenza: a multicenter study from Japan of the 2002-2003 influenza season. Clin Infect Dis 2005;40:1309-16.
26. Bowles SK, Lee W, Simor AE, et al. Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000. J Am Geriatr Soc 2002;50:608-16.
27. McCullers JA, Bartmess KC. Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae. J Infect Dis 2003;187:1000-9.
28. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families. N Engl J Med 2000;343:1282-9.
29. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without post-exposure prophylaxis. J Infect Dis 2004;189:440-9.
30. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 2001;285:748-54.
31. Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. JAMA 1999;282:31-5.
32. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999;341:1336-43.
33. Monto AS, Pichichero ME, Blanckenberg SJ, et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis 2002;186:1582-8.
34. Oxford J, Balasingam S, Lambkin R. A new millennium conundrum: how to use a powerful class of influenza anti-neuraminidase drugs (NAIs) in the community. J Antimicrob Chemother 2004;53:133-6.
35. Langley JM, Faughnan ME. Prevention of influenza in the general population. CMAJ 2004;171:1213-22.
36. Peters PH Jr, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001;49:1025-31.
37. Monto AS, Rotthoff J, Teich E, et al. Detection and control of influenza outbreaks in well-vaccinated nursing home populations. Clin Infect Dis 2004;39:459-64.
38. Harper SA, Fukuda K, Uyeki TM, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2004;53(RR-6):1-40.
39. Relenza (zanamivir for inhalation). Research Triangle Park, N.C.: Glaxo Wellcome, 2001.
40. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999;282:1240-6.
41. Tamiflu (oseltamivir phosphate) capsules. Nutley, N.J.: Roche Laboratories, 2000 (package insert).
42. Freund B, Gravenstein S, Elliott M, Miller I. Zanamivir: a review of clinical safety. Drug Saf 1999;21:267-81.
43. Zambon M, Hayden FG. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res 2001;49:147-56.
44. McKimm-Breschkin J, Trivedi T, Hampson A, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother 2003;47:2264-72.
45. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004;364:759-65.
46. Moscona A. Oseltamivir-resistant influenza? Lancet 2004;364:733-4.
47. Herlocher ML, Truscon R, Elias S, et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 2004;190:1627-30.
48. Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000;160:3243-7.
49. Cox NJ, Subbarao K. Influenza. Lancet 1999;354:1277-82.
50. Storch GA. Rapid diagnostic tests for influenza. Curr Opin Pediatr 2003;15:77-84.
51. Health Sciences Authority. Product safety alert: new preclinical findings on oseltamivir. March 2004. (Accessed September 2, 2005, at: http://www.hsa.gov.sg/docs/safetyalert_oseltamivir_Mar04.pdf.)
52. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 2005;352:333-40.
53. Li KS, Guan Y, Wang J, et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 2004;430:209-13.
54. Sẗhr K. Avian influenza and pandemics - research needs and opportunities. N Engl J Med 2005;352:405-7.
55. World Health Organization. Cumulative number of confirmed human cases of avian Influenza A/(H5N1) reported to WHO. 2005. (Accessed September 2, 2005, at http://www.who.int/csr/disease/avian_influenza/country/case_table_2005_08_05/en/ index.html.)
56. Monto AS. The threat of an avian influenza pandemic. N Engl J Med 2005;352:323-5. [Erratum, N Engl J Med 2005;352:1056.]
57. Hayden FG. Perspectives on antiviral use during pandemic influenza. Philos Trans R Soc Lond B Biol Sci 2001;356:1877-84.
58. Centers for Disease Control and Prevention. Update on influenza A(H5N1) and SARS: interim recommendations for enhanced U.S. surveillance, testing, and infection controls. February 3, 2004. (Accessed September 2, 2005, at http://www.cdc.gov/flu/avian/professional/han020302.htm.)
59. Commonwealth Scientific and Industrial Research Organization. CSIRO based drug effective against bird flu. (Accessed September 2, 2005, at http://www.csiro.au/index.asp?type=mediaRelease&id=PrBirdFlu5& stylesheet=mediaRelease.)
60. Trampuz A, Prabhu RM, Smith TF, Baddour LM. Avian influenza: a new pandemic threat? Mayo Clin Proc 2004;79:523-30. [Erratum, Mayo Clin Proc 2004;79:833.]
61. World Health Organization. WHO intercountry consultation: influenza A/H5N1 in humans in Asia, Manila May 6th-7th 2005. (Accessed September 2, 2005, at http://www.who.int/csr/disease/avian_influenza/H5N1IntercountryAssessment. pdf.)
62. Tumpey TM, Garcia-Sastre A, Mikulasova A, et al. Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A 2002;99:13849-54.
63. Leneva IA, Goloubeva O, Fenton RJ, Tisdale M, Webster RG. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob Agents Chemother 2001;45:1216-24.
64. Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 2000;48:101-15.
65. Mills CE, Robins JM, Lipsitch M. Transmissibility of 1918 pandemic influenza. Nature 2004;432:904-6.
66. Balicer RD, Huerta M, Grotto I. Tackling the next influenza pandemic. BMJ 2004;328:1391-2.
67. World Health Organization. WHO consultation on priority public health interventions before and during an influenza pandemic. April 2004. (Accessed September 2, 2005 at: http://www.who.int/csr/disease/avian_influenza/ consultation/en/.)